Treat-And-Extend Regimens with Anti-Vegf Agents in Retinal Diseases

Retina

Volumn 35, Issue 8, 2015, Pages 1489-1506

  Freund, K Bailey ^a   Korobelnik, Jean François ^b,c   Devenyi, Robert ^d   Framme, Carsten ^e   Galic, John ^f   Herbert, Edward ^g   Hoerauf, Hans ^h   Lanzetta, Paolo ⁱ   Michels, Stephan ^j   Mitchell, Paul ^k   Monés, Jordi ^l   Regillo, Carl ^m   Tadayoni, Ramin ⁿ   Talks, James ^o   Wolf, Sebastian ^p  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e University Childrens Hospital Hannover   (Germany)

^f Montreal Retina and Laser Institute   (Canada)

^g MUSGROVE PARK HOSPITAL   (United Kingdom)

^h UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

ⁱ UNIVERSITY OF UDINE   (Italy)

^j UNIVERSITY OF ZURICH   (Switzerland)

^k UNIVERSITY OF SYDNEY   (Australia)

^l HOSPITAL QUIRÓN   (Spain)

^m WILLS EYE HOSPITAL   (United States)

ⁿ HÔPITAL LARIBOISIÈRE   (France)

^o NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^p UNIVERSITY OF BERN   (Switzerland)

more..

Author keywords

aflibercept; age related macular degeneration; algorithm; anti VEGF agents; bevacizumab; diabetic macular edema; ranibizumab; retinal vein occlusion; treat and extend

Indexed keywords

AFLIBERCEPT; BIOLOGICAL MARKER; RANIBIZUMAB; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ALGORITHM; CLINICAL PRACTICE; CONSENSUS; DISEASE ACTIVITY; FOLLOW UP; HUMAN; LASER COAGULATION; OPTICAL COHERENCE TOMOGRAPHY; PATIENT MONITORING; RETINA DISEASE; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CONSENSUS DEVELOPMENT; DIABETIC RETINOPATHY; MACULAR DEGENERATION; MACULAR EDEMA; PRACTICE GUIDELINE; RETINAL VEIN OCCLUSION;

ALGORITHMS; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DIABETIC RETINOPATHY; HUMANS; MACULAR DEGENERATION; MACULAR EDEMA; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINAL VEIN OCCLUSION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84938784440     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000627     Document Type: Review

References (62)

1. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic mac-ular edema: pathogenesis and treatment. Surv Ophthalmol 2009;54:1-32.
2. Augustin AJ, Kirchhof J. Inflammation and the pathogenesis of age-related macular degeneration. Expert Opin Ther Targets 2009;13:641-651.
3. Brand CS. Management of retinal vascular diseases: a patient-centric approach. Eye (Lond) 2012;26(suppl 2):S1-S16.
4. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-1411.
5. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-1908.
6. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intra-vitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-583.
7. Cohen SY, Dubois L, Ayrault S, et al. Ranibizumab for exudative AMD in a clinical setting: differences between 2007 and 2010. Graefes Arch Clin Exp Ophthalmol 2013;251:2499-2503.
8. Jeng KW, Wilgucki J, Halperin S, et al. Retina specialists treating age-related macular degeneration recommend different approaches for patients than they would choose for themselves. Retina 2014;34:1796-1801.
9. Xing L, Dorrepaal SJ, Gale J. Survey of intravitreal injection techniques and treatment protocols among retina specialists in Canada. Can J Ophthalmol 2014;49:261-266.
10. Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 2014;98:1144-1167.
11. Mantel I, Deli A, Iglesias K, Ambresin A. Prospective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2013;251:697-704.
12. Fauser S, Schwabecker V, Muether PS. Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration. Am J Ophthalmol 2014;158:532-536.
13. Chakravarthy U, Soubrane G, Bandello F, et al. Evolving European guidance on the medical management of neovascular age related macular degeneration. Br J Ophthalmol 2006;90:1188-1196.
14. Engelbert M, Zweifel SA, Freund KB. "Treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina 2009;29:1424-1431.
15. Engelbert M, Zweifel SA, Freund KB. Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified "treat and extend" dosing regimen of intravitreal antivascular endothelial growth factor therapy. Retina 2010;30:1368-1375.
16. Gupta OP, Shienbaum G, Patel AH, et al. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 2010;117:2134-2140.
17. Shienbaum G, Gupta OP, Fecarotta C, et al. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact. Am J Ophthalmol 2012;153:468-473.
18. Fung AT, Kumar N, Vance SK, et al. Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study). Eye (Lond) 2012; 26: 1181-1187.
19. Toalster N, Russell M, Ng PA. 12-month prospective trial of inject and extend regimen for ranibizumab treatment of age-related macular degeneration. Retina 2013;33:1351-1358.
20. Abedi F, Wickremasinghe S, Islam AF, et al. Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years. Retina 2014;34:1531-1538.
21. Rush RB, Simunovic MP, Vandiver L, et al. Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics. Retina 2014; 34:846-852.
22. Rush RB, Rush SW, Aragon AV, Ysasaga JE. Evaluation of choroidal neovascularization with indocyanine green angiography in neovascular age-related macular degeneration subjects undergoing intravitreal bevacizumab therapy. Am J Ophthalmol 2014;158:337-344.
23. Berg K, Pedersen TR, Sandvik L, Bragadottir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 2015;122:146-152.
24. Rayess N, Houston SK III, Gupta OP, et al. Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen. Am J Ophthalmol 2015;159: 3-8.
25. Oubraham H, Cohen SY, Samimi S, et al. Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina 2011;31:26-30.
26. Hatz K, Pruente C. Changing from a pro re nata treatment regimen to a treat and extend regimen in neovascular age-related macular degeneration. Abstract 3812-B0122. Presented at: 13th European Society of Retina Specialists (EURETINA) Congress; September 26-29, 2013; Hamburg, Germany.
27. Calvo P, Wang Y, Ferreras A, et al. Treat and extend versus treat and observe in wet age-related macular degeneration patients treated with ranibizumab: 3-year surveillance period [abstract]. J Clin Exp Ophthalmol 2014;5:324.
28. Brady CJ, Alshareef R, Witkin AJ, Regillo CD. A treat and extend regimen using anti-VEGF therapies for central retinal vein occlusion. Poster B0123. Presented at: 2013 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO); May 5-9, 2013; Seattle, WA.
29. Campochiaro PA, Sophie R, Pearlman J, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 2014;121: 209-219.
30. Rush RB, Simunovic MP, Aragon AV, Ysasaga JE. Treat-and-extend intravitreal bevacizumab for branch retinal vein occlusion. Ophthalmic Surg Lasers Imaging Retina 2014;45:212-216.
31. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-2548.
32. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravi-treal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 2014;121:193-201.
33. Stewart MW. Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF. Expert Rev Clin Pharmacol 2014;7:167-180.
34. Ogura Y, Roider J, Korobelnik JF, et al. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Oph-thalmol 2014;158:1032-1038.
35. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2014; 121:2247-2254.
36. Pruente C. Efficacy and safety of ranibizumab in two treat-and-extend versus pro-re-nata regimes in patients with visual impairment due to diabetic macular edema: 24-month results of RETAIN study. Invest Ophthalmol Vis Sci 2015;55:1700.
37. Pierro L, Zampedri E, Milani P, et al. Spectral domain OCT versus time domain OCT in the evaluation of macular features related to wet age-related macular degeneration. Clin Ophthal-mol 2012;6:219-223.
38. Querques G, Forte R, Berboucha E, et al. Spectral-domain versus time domain optical coherence tomography before and after ranibizumab for age-related macular degeneration. Ophthalmic Res 2011;46:152-159.
39. Sayanagi K, Sharma S, Yamamoto T, et al. Comparison of spectral-domain versus time-domain optical coherence tomography in management of age-related macular degeneration with ranibizumab. Ophthalmology 2009;116:947-955.
40. Major JC Jr., Wykoff CC, Mariani AF, et al. Comparison of spectral-domain and time-domain optical coherence tomography in the detection of neovascular age-related macular degeneration activity. Retina 2014;34:48-54.
41. Khurana RN, Dupas B, Bressler NM. Agreement of time-domain and spectral-domain optical coherence tomography with fluorescein leakage from choroidal neovascularization. Ophthalmology 2010;117:1376-1380.
42. Barteselli G, Chhablani J, Lee SN, et al. Safety and efficacy of oral fluorescein angiography in detecting macular edema in comparison with spectral-domain optical coherence tomography. Retina 2013;33:1574-1583.
43. Houston SK, Rayess N, Ho AC, Regillo CD. Influence of vitreomacular interface on anti-VEGF therapy using treat and extend treatment protocol for age-related macular degeneration. Poster B0268. Presented at: 2014 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO); May 4-8, 2014; Orlando, FL.
44. Mrejen S, Jung JJ, Gallego-Pinazo R, et al. Long-term visual outcomes for a treat and extend anti-VEGF regimen in eyes with neovascular age-related macular degeneration. Poster C0272. Presented at: 2014 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO); May 4-8, 2014; Orlando, FL.
45. Hines J, Ecker SM, Glaser BM. A vitreous proteomic bio-marker panel that can guide the choice of patients with wet AMD who will respond to treat and extend therapy: personalized medicine applied to AMD. Poster 191. Presented at: 2013 Annual Meeting of the American Academy of Ophthalmology (AAO); November 16-19, 2013; New Orleans, LA.
46. Glaser BM. Vitreous proteomics reveals a biomarker panel that predicts the response of patients with wet AMD to treat and extend therapy. Abstract. Presented at: 31st Annual Meeting of the American Society of Retina Specialists (ASRS); August 24-28, 2013; Toronto, ON, Canada.
47. Lindner M, Bezatis A, Czauderna J, et al. Choroidal thickness in geographic atrophy secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci 2015. pii: IOVS-14-14933; 56:875-882.
48. Xu L, Mrejen S, Jung JJ, et al. Geographic atrophy in patients receiving anti-vascular endothelial growth factor for neovascu-lar age-related macular degeneration. Retina 2015;35:176-186.
49. Cho HJ, Yoo SG, Kim HS, et al. Risk factors for geographic atrophy after intravitreal ranibizumab injections for retinal angiomatous proliferation. Am J Ophthalmol 2015;159: 285-292.e1.
50. Marsiglia M, Boddu S, Bearelly S, et al. Association between geographic atrophy progression and reticular pseudodrusen in eyes with dry age-related macular degeneration. Invest Oph-thalmol Vis Sci 2013;54:7362-7369.
51. Marsiglia M, Boddu S, Chen C, et al. Correlation between neovascular lesion type and clinical characteristics of nonneo-vascular fellow eyes in patients with unilateral, neovascular age-related macular degeneration. Retina 2015;35:966-974.
52. Mathalone N, Arodi-Golan A, Sar S, et al. Sustained elevation of intraocular pressure after intravitreal injections of bevacizu-mab in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2012;250:1435-1440.
53. Hoang QV, Tsuang AJ, Gelman R, et al. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy. Retina 2013;33: 179-187.
54. Yannuzzi NA, Patel SN, Bhavsar KV, et al. Predictors of sustained intraocular pressure elevation in eyes receiving intravi-treal anti-vascular endothelial growth factor therapy. Am J Ophthalmol 2014;158:319-327.e2.
55. Aref AA. Management of immediate and sustained intraocular pressure rise associated with intravitreal antivascular endothe-lial growth factor injection therapy. Curr Opin Ophthalmol 2012;23:105-110.
56. Pang CE, Mrejen S, Hoang QV, et al. Association between needle size, postinjection reflux, and intraocular pressure spikes after intravitreal injections. Retina 2015. Epub ahead of print.
57. Parlak M, Oner FH, Saatci AO. The long-term effect of intra-vitreal ranibizumab on retinal nerve fiber layer thickness in exudative age-related macular degeneration. Int Ophthalmol 2014. Epub ahead of print.
58. Curtis LH, Hammill BG, Qualls LG, et al. Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 medicare beneficiaries. Am J Ophthalmol 2012;153:1116-1124.
59. Lad EM, Hammill BG, Qualls LG, et al. Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries. Am J Ophthalmol 2014;158:537-543.
60. Rasmussen A, Bloch SB, Fuchs J, et al. A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration. Ophthalmology 2013;120: 2630-2636.
61. Bhavsar KV, Freund KB. Retention of good visual acuity in eyes with neovascular age-related macular degeneration and chronic refractory subfoveal subretinal fluid. Saudi J Ophthal-mol 2014;28:129-133.
62. Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 2015;99:220-226.